Efficacy and safety of Y-3 intracalvariosseous injection versus intravenous injection in the treatment of acute large hemispheric infarction (SOLUTION-2): rationale and design of a multicentre, prospective, randomised, open-label, blind endpoint (PROBE) trial.

Wang N, Zhang M, Yang M, Liu W, Liu W, Ou Y, Zhou M, Wang X, Sun Z, Pan Y, Wang Y, Wang Y

Open source

DOI
10.1136/svn-2024-004011
Published
2026 Mar 4
Container
Stroke and vascular neurology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1136/svn-2024-004011,
  title = {Efficacy and safety of Y-3 intracalvariosseous injection versus intravenous injection in the treatment of acute large hemispheric infarction (SOLUTION-2): rationale and design of a multicentre, prospective, randomised, open-label, blind endpoint (PROBE) trial.},
  author = {Wang N and Zhang M and Yang M and Liu W and Liu W and Ou Y and Zhou M and Wang X and Sun Z and Pan Y and Wang Y and Wang Y},
  year = {2026},
  journal = {Stroke and vascular neurology},
  doi = {10.1136/svn-2024-004011},
  url = {https://doi.org/10.1136/svn-2024-004011}
}

RIS

TY  - JOUR
TI  - Efficacy and safety of Y-3 intracalvariosseous injection versus intravenous injection in the treatment of acute large hemispheric infarction (SOLUTION-2): rationale and design of a multicentre, prospective, randomised, open-label, blind endpoint (PROBE) trial.
AU  - Wang N
AU  - Zhang M
AU  - Yang M
AU  - Liu W
AU  - Liu W
AU  - Ou Y
AU  - Zhou M
AU  - Wang X
AU  - Sun Z
AU  - Pan Y
AU  - Wang Y
AU  - Wang Y
PY  - 2026
JO  - Stroke and vascular neurology
DO  - 10.1136/svn-2024-004011
UR  - https://doi.org/10.1136/svn-2024-004011
ER  - 

APA

N, W., M, Z., M, Y., W, L., W, L., Y, O., M, Z., X, W., Z, S., Y, P., Y, W., & Y, W. (2026). Efficacy and safety of Y-3 intracalvariosseous injection versus intravenous injection in the treatment of acute large hemispheric infarction (SOLUTION-2): rationale and design of a multicentre, prospective, randomised, open-label, blind endpoint (PROBE) trial.. Stroke and vascular neurology. https://doi.org/10.1136/svn-2024-004011

Source records